| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $1,300,167 | 6 | 100 |
| Chin Peter Scott | Chief Medical Officer | 0 | $0 | 1 | $36,868 | $-36,868 |
| Thornberry Nancy | director | 0 | $0 | 1 | $261,929 | $-261,929 |
| Schuth Alexander O. | COFO and Secretary | 0 | $0 | 3 | $420,604 | $-420,604 |
| Watts Ryan J. | President and CEO | 0 | $0 | 1 | $580,767 | $-580,767 |
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, …
Over the last 12 months, insiders at Denali Therapeutics Inc. have bought $0 and sold $1.3M worth of Denali Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Denali Therapeutics Inc. have bought $0 and sold $7.11M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 550,000 shares for transaction amount of $9.9M was made by BRATTON DOUGLAS K (10 percent owner) on 2017‑12‑12.
| 2026-09-04 | Sale | Chin Peter Scott | Chief Medical Officer | 1,654 0.0009% | $22.29 | $36,868 | -12.70% | |
| 2026-09-02 | Sale | Thornberry Nancy | director | 11,439 0.0072% | $22.90 | $261,929 | -13.70% | |
| 2026-09-01 | Sale | Schuth Alexander O. | COFO and Secretary | 2,768 0.0018% | $23.44 | $64,882 | -14.85% | |
| 2026-08-11 | Sale | Schuth Alexander O. | COFO and Secretary | 2,857 0.0018% | $25.07 | $71,625 | -17.09% | |
| 2026-01-06 | Sale | Watts Ryan J. | President and CEO | 35,198 0.0232% | $16.50 | $580,767 | +19.44% | |
| 2026-01-06 | Sale | Schuth Alexander O. | COFO and Secretary | 17,218 0.0114% | $16.50 | $284,097 | +19.44% | |
| 2025-08-13 | Sale | Ho Carole | Chief Medical Officer | 806 0.0005% | $14.64 | $11,800 | +30.86% | |
| 2025-08-12 | Sale | Schuth Alexander O. | COFO and Secretary | 2,937 0.002% | $13.58 | $39,884 | +46.37% | |
| 2025-08-12 | Sale | Ho Carole | Chief Medical Officer | 2,937 0.002% | $13.58 | $39,884 | +46.37% | |
| 2025-07-09 | Sale | Watts Ryan J. | President and CEO | 495,282 0.3409% | $15.00 | $7.43M | +21.07% | |
| 2025-01-07 | Sale | Watts Ryan J. | President and CEO | 7,650 0.0052% | $20.81 | $159,197 | -28.26% | |
| 2025-01-07 | Sale | Schuth Alexander O. | COFO and Secretary | 2,907 0.002% | $20.81 | $60,495 | -28.26% | |
| 2025-01-07 | Sale | Ho Carole | Chief Medical Officer | 2,907 0.002% | $20.81 | $60,495 | -28.26% | |
| 2025-01-07 | Sale | Krognes Steve E. | director | 3,339 0.0023% | $20.81 | $69,485 | -28.26% | |
| 2025-01-06 | Sale | Watts Ryan J. | President and CEO | 29,266 0.0208% | $20.22 | $591,759 | -23.34% | |
| 2025-01-06 | Sale | Schuth Alexander O. | COFO and Secretary | 12,255 0.0087% | $20.22 | $247,796 | -23.34% | |
| 2025-01-06 | Sale | Ho Carole | Chief Medical Officer | 12,255 0.0087% | $20.22 | $247,796 | -23.34% | |
| 2025-01-02 | Sale | SATO VICKI L | director | 3,080 0.0021% | $20.91 | $64,403 | -27.09% | |
| 2024-12-31 | Sale | Krognes Steve E. | director | 30,000 0.0207% | $20.25 | $607,500 | -25.44% | |
| 2024-11-11 | Sale | Schenkein David P | director | 59,441 0.0421% | $32.51 | $1.93M | -51.88% |
| BRATTON DOUGLAS K | 10 percent owner | 9984836 6.2465% | $194.21M | 1 | 12 | <0.0001% |
$52,263,649 | 70 | 1.18% | $2.49B | |
$586,486,795 | 47 | 4.28% | $2.38B | |
$104,428,685 | 44 | 22.55% | $3.78B | |
$1,275,975,557 | 32 | 19.44% | $3.54B | |
$1,603,489 | 30 | 98.90% | $2.33B |
| Increased Positions | 141 | +52.81% | 24M | +16.77% |
| Decreased Positions | 112 | -41.95% | 12M | -8.57% |
| New Positions | 53 | New | 5M | New |
| Sold Out Positions | 38 | Sold Out | 2M | Sold Out |
| Total Postitions | 296 | +10.86% | 152M | +8.19% |
| Blackrock, Inc. | $199,952.00 | 7.88% | 12.29M | +236,281 | +1.96% | 2025-09-30 |
| Vanguard Group Inc | $195,125.00 | 7.69% | 11.99M | +182,183 | +1.54% | 2025-09-30 |
| Baillie Gifford & Co | $188,595.00 | 7.43% | 11.59M | -363,738 | -3.04% | 2025-09-30 |
| Fmr Llc | $103,157.00 | 4.06% | 6.34M | -1M | -15.89% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $91,739.00 | 3.61% | 5.64M | +2M | +73.66% | 2025-09-30 |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Ame | $88,916.00 | 3.5% | 5.47M | -797,240 | -12.73% | 2025-09-30 |
| State Street Corp | $88,904.00 | 3.5% | 5.46M | +946,267 | +20.94% | 2025-09-30 |
| Temasek Holdings (Private) Ltd | $87,139.00 | 3.43% | 5.36M | 0 | 0% | 2025-09-30 |
| Capital Research Global Investors | $77,459.00 | 3.05% | 4.76M | +10,279 | +0.22% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $74,327.00 | 2.93% | 4.57M | -2M | -30.6% | 2025-09-30 |